• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

IDRA (Idera Pharmaceuticals Inc.)
Last Trade 2.57 Dividend/Share 0 PE Ratio -1.12
Date May 24-2019 Dividend Yield 0.000 Return on Assets -61.98
Change -0.03 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -2.27 Price/Sale 179.009
Ask 0 LatestEPS Date 2018-12-31 Price to Book 1.31
Volume 9139 EPS ttm -2.300 Institutional % 55.6
Avg Volume 0.46M Shares Outstanding 28.02M Insider % null
Open 2.62 Float 26.59M Short Ratio null
Prev Close 2.6 Return On Equity -69.66 5 Year Change % -0.877
High 2.69 Consensus EPS -0.46 2 Year Change % -0.809
Low 2.49 No. of Estimate 4.000 1 Year Change % -0.830
52 Week High 17.12 EPS Surprise $ null YTD Change % -0.270
52 Week Low 2.25 EPS Surprise Percent 0 6 Month Change % -0.654
52 Week Change -82.984 EBITDA 0M 3 Month Change % -0.120
50 Day MA 2.8248 Revenue 0M 1 Month Change % -0.055
200 Day MA Gross Profit 0M 5 Day Change % -0.015
Market Cap 72.86M Cash 0M 30 Day Change % -0.082
Beta 2.548678 Debt 0M Stock Exchange NASDAQ Capital Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer?s disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.